Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Kat. Nr. | Arten | Produktbeschreibung | Struktur | Reinheit | Merkmal |
---|---|---|---|---|---|
TF3-C52H3 | Cynomolgus | Cynomolgus Coagulation Factor III / Tissue Factor Protein, His Tag (active enzyme, MALS verified) |
|
||
TF3-H5253 | Human | Human Coagulation Factor III / Tissue Factor Protein, Fc Tag (active enzyme) |
|
||
TF3-M52H3 | Mouse | Mouse Coagulation Factor III / Tissue Factor Protein, His Tag (MALS verified) |
|
||
TF3-H52H5 | Human | Human Coagulation Factor III / Tissue Factor Protein, His Tag (active enzyme, MALS verified) |
|
Anti-TF mAb immobilized on CM5 Chip can bind Human Tissue Factor, Fc Tag (Cat. No. TF3-H5253) with an affinity constant of 2.38 nM as determined in SPR assay (Biacore T200) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Tisotumab vedotin | TF-011-MMAE | Approved | Genmab A/S | HuMax-TF, TIVDAK | United States | Uterine Cervical Neoplasms | Seagen Inc | 2021-09-20 | Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Tisotumab vedotin | TF-011-MMAE | Approved | Genmab A/S | HuMax-TF, TIVDAK | United States | Uterine Cervical Neoplasms | Seagen Inc | 2021-09-20 | Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Anpocogin | AB-201 | Phase 3 Clinical | Dendreon Uk Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
XNW-28012 | XNW-28012; XNW28012 | Phase 2 Clinical | Shanghai Cigna Biotech Pharmaceutical Co Ltd | Solid tumours | Details |
MRG-004A | MRG004A | Phase 2 Clinical | Solid tumours | Details | |
XB-002 | XB-002; ICON-2 | Phase 1 Clinical | Iconic Therapeutics Inc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Urogenital Neoplasms; Esophageal Squamous Cell Carcinoma; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
Anpocogin | AB-201 | Phase 3 Clinical | Dendreon Uk Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
XNW-28012 | XNW-28012; XNW28012 | Phase 2 Clinical | Shanghai Cigna Biotech Pharmaceutical Co Ltd | Solid tumours | Details |
MRG-004A | MRG004A | Phase 2 Clinical | Solid tumours | Details | |
XB-002 | XB-002; ICON-2 | Phase 1 Clinical | Iconic Therapeutics Inc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Urogenital Neoplasms; Esophageal Squamous Cell Carcinoma; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
This web search service is supported by Google Inc.